Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-11-28
2006-11-28
Habte, Kahsay (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S224000, C544S238000, C514S252010, C206S570000
Reexamination Certificate
active
07141572
ABSTRACT:
Hydrazono-malonitrile derivatives of the formula (I) in which R1, R2, R3, R3′and R4have the meanings given in Claim1act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS
REFERENCES:
patent: 98 06704 (1998-02-01), None
patent: 99 65880 (1999-12-01), None
patent: 00 26201 (2000-05-01), None
patent: 01 04099 (2001-01-01), None
Hungarian Abstract P0001760 (May 28, 2001).
Beier Norbert
Eggenweiler Hans-Michael
Ehring Thomas
Schelling Pierre
Wolf Michael
Habte Kahsay
Merck Patent Gesellschaft
Millen White Zelano & Branigan P.C.
LandOfFree
Hydrazono-malonitriles does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydrazono-malonitriles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydrazono-malonitriles will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3661292